CNBX Pharmaceuticals Inc.
CNBX
$0.00
$0.00-20.00%
OTC PK
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 08/31/2025 | 05/31/2025 | 02/28/2025 | 11/30/2024 | 08/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -100.00% | -100.00% | -91.87% | -68.31% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -100.00% | -100.00% | -91.87% | -68.31% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -100.00% | -100.00% | -93.11% | -69.82% |
| SG&A Expenses | -47.61% | -52.09% | -49.71% | -47.57% | -43.03% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -61.92% | -78.92% | -75.56% | -61.09% | -46.84% |
| Operating Income | 53.42% | 71.91% | 57.03% | 40.78% | 37.40% |
| Income Before Tax | 54.83% | 81.42% | 76.03% | 84.39% | 81.26% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 54.83% | 81.42% | 76.03% | 84.39% | 81.26% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 54.83% | 81.42% | 76.03% | 84.39% | 81.26% |
| EBIT | 53.42% | 71.91% | 57.03% | 40.78% | 37.40% |
| EBITDA | 60.94% | 75.86% | 51.91% | 33.59% | 33.60% |
| EPS Basic | 76.96% | 85.59% | 83.88% | 98.72% | 98.62% |
| Normalized Basic EPS | 71.43% | 75.58% | 76.40% | 90.83% | 95.55% |
| EPS Diluted | 76.96% | 85.59% | 83.88% | 98.72% | 98.62% |
| Normalized Diluted EPS | 71.43% | 75.58% | 76.40% | 90.83% | 95.55% |
| Average Basic Shares Outstanding | 199.26% | 21.08% | 37.48% | 99.86% | 238.86% |
| Average Diluted Shares Outstanding | 199.26% | 21.08% | 37.48% | 99.86% | 238.86% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |